How do orphan disease patients live during the pandemic of Omicron variant? A nationwide survey of spinal muscular atrophy patients in China
暂无分享,去创建一个
F. Song | Jianxiong Shen | Xuan Huang | Xin Chen | Y. Jiao | Weiyun Chen | H. Xiong | Peiyu Sun | Zhen Wang | Junduo Zhao | Y. Dai | Haoyu Cai | Jiayi Shen
[1] L. Zheng,et al. Impact of National Omicron Outbreak at the end of 2022 on the future outlook of COVID-19 in China , 2023, Emerging microbes & infections.
[2] Jing-wen Ai,et al. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave , 2022, Emerging microbes & infections.
[3] B. Cao,et al. Protein-based vaccine as the booster dose for adults: evidence and beyond , 2022, The Lancet Infectious Diseases.
[4] J. Kinge,et al. Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants , 2022, JAMA internal medicine.
[5] C. Steves,et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study , 2022, The Lancet.
[6] T. Burki. COVID-19 vaccination in young children , 2022, The Lancet Respiratory Medicine.
[7] S. Schrag,et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. , 2022, JAMA.
[8] N. Sewankambo,et al. Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries , 2022, JAMA pediatrics.
[9] Suresh Kumar,et al. Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein , 2021, Journal of medical virology.
[10] L. Giacomelli,et al. Effect of the COVID-19 Pandemic on Children With SMA Receiving Nusinersen: What Is Missed and What Is Gained? , 2021, Frontiers in Neurology.
[11] C. Ortez,et al. COVID-19 in children with neuromuscular disorders , 2021, Journal of Neurology.
[12] W. Wu,et al. Bioinformatic analysis of SMN1–ACE/ACE2 interactions hinted at a potential protective effect of spinal muscular atrophy against COVID-19-induced lung injury , 2020, Briefings Bioinform..
[13] M. Temsah,et al. COVID-19 infection prevalence in pediatric population: Etiology, clinical presentation, and outcome , 2020, Journal of Infection and Public Health.
[14] R. Finkel,et al. Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study , 2020, Neurology.
[15] R. Finkel,et al. Spinal muscular atrophy — insights and challenges in the treatment era , 2020, Nature Reviews Neurology.
[16] M. C. Jaklevic. Oral Drug Approved for Spinal Muscular Atrophy. , 2020, JAMA.
[17] Y. Péréon,et al. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network , 2020, Revue Neurologique.
[18] W. Hugentobler,et al. Seasonality of Respiratory Viral Infections. , 2020, Annual review of virology.
[19] V. Prasad. Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little? , 2017, JAMA pediatrics.
[20] Hanns Lochmüller,et al. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review , 2017, Orphanet Journal of Rare Diseases.